Breaking Finance News

ValuEngine upgraded MYOS RENS Technology Inc (NASDAQ:MYOS) to Sell in a report released today.

Just yesterday MYOS RENS Technology Inc (NASDAQ:MYOS) traded -5.37% lower at $2.08. MYOS RENS Technology Inc’s 50-day moving average is $1.79 and its 200-day moving average is $2.45. The last stock price is down -42.53% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.05% over the same time period. 23,537 shares of MYOS traded hands, down from an average trading volume of 39,409

ValuEngine has upgraded MYOS RENS Technology Inc (NASDAQ:MYOS) to Sell in a report released on 7/6/2017.

Recent Performance Chart

MYOS RENS Technology Inc (NASDAQ:MYOS)

MYOS RENS Technology Inc has 52 week low of $1.02 and a 52 week high of $6.98 and has a market capitalization of $0.

Brief Synopsis On MYOS RENS Technology Inc (NASDAQ:MYOS)

MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *